Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).

被引：103

作者：

Camidge, D. R.

Bang, Y.

Kwak, E. L.

Shaw, A. T.

Iafrate, A. J.

Maki, R. G.

Solomon, B. J.

Ou, S. I.

Salgia, R.

Wilner, K. D.

Costa, D. B.

Shapiro, G.

LoRusso, P.

Stephenson, P.

Tang, Y.

Ruffner, K.

Clark, J. W.

机构：

[1] Univ Colorado Denver, Aurora, CO USA

[2] Seoul Natl Univ, Coll Med, Seoul, South Korea

[3] Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA

[4] Harvard Univ, Sch Med, Boston, MA USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[8] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[9] Univ Calif Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Irvine, CA USA

[10] Univ Chicago, Chicago, IL 60637 USA

[11] Pfizer Oncol, San Diego, CA USA

[12] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA

[13] Dana Farber Canc Inst, Boston, MA 02115 USA

[14] Karmanos Canc Inst, Detroit, MI USA

[15] Rho Inc, Chapel Hill, NC USA

[16] Pfizer Inc, San Diego, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.2501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2501

引用

页数：1